Loading...

Medigard

ASX:MGZ
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MGZ
ASX
A$3M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Medigard Limited develops various medical instruments in Australia. The last earnings update was 50 days ago. More info.


Add to Portfolio Compare Print
MGZ Share Price and Events
7 Day Returns
0%
ASX:MGZ
4%
AU Medical Equipment
0.3%
AU Market
1 Year Returns
11.1%
ASX:MGZ
-2.2%
AU Medical Equipment
5.2%
AU Market
MGZ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medigard (MGZ) 0% 0% 0% 11.1% -37.5% -16.7%
AU Medical Equipment 4% 0.8% 3.1% -2.2% 41.7% 108.8%
AU Market 0.3% 1% 7.2% 5.2% 19.2% 4.9%
1 Year Return vs Industry and Market
  • MGZ outperformed the Medical Equipment industry which returned -2.2% over the past year.
  • MGZ outperformed the Market in Australia which returned 5.2% over the past year.
Price Volatility
MGZ
Industry
5yr Volatility vs Market

MGZ Value

 Is Medigard undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Medigard is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Medigard has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Medigard. This is due to cash flow or dividend data being unavailable. The share price is A$0.02.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medigard's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medigard's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:MGZ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.01
ASX:MGZ Share Price ** ASX (2019-03-04) in AUD A$0.02
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.18x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medigard.

ASX:MGZ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:MGZ Share Price ÷ EPS (both in AUD)

= 0.02 ÷ -0.01

-2.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medigard is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Medigard is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Medigard's expected growth come at a high price?
Raw Data
ASX:MGZ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.66x
Australia Market PEG Ratio Median Figure of 361 Publicly-Listed Companies 1.36x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medigard, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medigard's assets?
Raw Data
ASX:MGZ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$-0.01
ASX:MGZ Share Price * ASX (2019-03-04) in AUD A$0.02
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.69x
ASX:MGZ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:MGZ Share Price ÷ Book Value per Share (both in AUD)

= 0.02 ÷ -0.01

-3.34x

* Primary Listing of Medigard.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medigard has negative assets, we can't compare the value of its assets to the AU Medical Equipment industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Medigard's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Medical Equipment industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Medigard's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Medigard has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MGZ Future Performance

 How is Medigard expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medigard has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medigard expected to grow at an attractive rate?
  • Unable to compare Medigard's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Medigard's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Medigard's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:MGZ Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.6%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:MGZ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:MGZ Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 0 -1
2018-09-30 0 0 -1
2018-06-30 0 0 -1
2018-03-31 0 0 -1
2017-12-31 0 0 -1
2017-09-30 0 0 0
2017-06-30 0 0 0
2017-03-31 0 0 0
2016-12-31 0 0 0
2016-09-30 0 0 0
2016-06-30 0 0 0
2016-03-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Medigard is high growth as no earnings estimate data is available.
  • Unable to determine if Medigard is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:MGZ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Medigard Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MGZ Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00
2016-09-30 0.00
2016-06-30 0.00
2016-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Medigard will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Medigard's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  2. Medigard's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Medigard's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medigard has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MGZ Past Performance

  How has Medigard performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medigard's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medigard does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Medigard's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medigard's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Medigard's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medigard Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:MGZ Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.02 -0.82 0.75
2018-09-30 0.03 -0.72 0.56
2018-06-30 0.04 -0.61 0.37
2018-03-31 0.05 -0.60 0.19
2017-12-31 0.07 -0.59 0.01
2017-09-30 0.07 -0.35 0.01
2017-06-30 0.07 -0.12 0.01
2017-03-31 0.07 -0.14 0.01
2016-12-31 0.07 -0.15 0.01
2016-09-30 0.06 -0.03 0.01
2016-06-30 0.04 0.08 0.01
2016-03-31 0.02 -0.07 0.01
2015-12-31 0.00 -0.21 0.01
2015-09-30 0.00 -0.40 0.01
2015-06-30 0.00 -0.59 0.01
2015-03-31 0.00 -0.48 0.03
2014-12-31 0.00 -0.38 0.06
2014-09-30 0.00 -0.35 0.06
2014-06-30 0.00 -0.33 0.06
2014-03-31 0.00 -0.31 0.06
2013-12-31 0.00 -0.30 0.06
2013-09-30 0.00 -0.31 0.06
2013-06-30 0.01 -0.32 0.06
2013-03-31 0.01 -0.32 0.10
2012-12-31 0.01 -0.32 0.13
2012-09-30 0.03 -0.33 0.13
2012-06-30 0.05 -0.33 0.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medigard has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Medigard has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medigard improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Medigard's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medigard has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MGZ Health

 How is Medigard's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medigard's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medigard's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Medigard has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medigard's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Medigard has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medigard Company Filings, last reported 3 months ago.

ASX:MGZ Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -0.81 0.89 0.04
2018-09-30 -0.81 0.89 0.04
2018-06-30 -0.66 1.02 0.38
2018-03-31 -0.66 1.02 0.38
2017-12-31 -0.54 1.16 0.56
2017-09-30 -0.54 1.16 0.56
2017-06-30 -0.72 0.84 0.08
2017-03-31 -0.72 0.84 0.08
2016-12-31 -0.64 0.89 0.18
2016-09-30 -0.64 0.89 0.18
2016-06-30 -0.60 0.93 0.26
2016-03-31 -0.60 0.93 0.26
2015-12-31 -0.49 0.54 0.01
2015-09-30 -0.49 0.54 0.01
2015-06-30 -0.68 0.89 0.16
2015-03-31 -0.68 0.89 0.16
2014-12-31 -0.28 0.39 0.03
2014-09-30 -0.28 0.39 0.03
2014-06-30 -0.10 0.21 0.02
2014-03-31 -0.10 0.21 0.02
2013-12-31 0.10 0.08 0.05
2013-09-30 0.10 0.08 0.05
2013-06-30 0.23 0.00 0.10
2013-03-31 0.23 0.00 0.10
2012-12-31 0.40 0.00 0.19
2012-09-30 0.40 0.00 0.19
2012-06-30 0.55 0.00 0.32
  • Medigard has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Medigard's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Medigard has less than a year of cash runway based on current free cash flow.
  • Medigard has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.1% each year.
X
Financial health checks
We assess Medigard's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medigard has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MGZ Dividends

 What is Medigard's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medigard dividends.
If you bought A$2,000 of Medigard shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medigard's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medigard's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:MGZ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.6%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medigard has not reported any payouts.
  • Unable to verify if Medigard's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medigard's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medigard has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medigard's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medigard afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medigard has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MGZ Management

 What is the CEO of Medigard's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Medigard has no CEO, or we have no data on them.
Management Team

Patricia Boero

TITLE
CFO & Company Secretary
COMPENSATION
A$85K
TENURE
15.3 yrs

Ian Dixon

TITLE
Chairman of Scientific & Medical Advisory Panel and Executive Director
COMPENSATION
A$140K

Ross Cali

TITLE
Head of Product Development

Aaron Rodd

TITLE
Design Technical Consultant
Board of Directors Tenure

Average tenure of the Medigard board of directors in years:

1.5
Average Tenure
  • The average tenure for the Medigard board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chris Bishop

TITLE
Non-Executive Chairman
COMPENSATION
A$36K
TENURE
1.5 yrs

Patricia Boero

TITLE
CFO & Company Secretary
COMPENSATION
A$85K
TENURE
13.1 yrs

Ian Dixon

TITLE
Chairman of Scientific & Medical Advisory Panel and Executive Director
COMPENSATION
A$140K
TENURE
1.3 yrs

Don Channer

TITLE
Non-Executive Director
AGE
79

Craig Cameron

TITLE
Non-Executive Director
COMPENSATION
A$24K
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
31. Jul 18 Buy Christopher Bishop Individual 31. Jul 18 31. Jul 18 3,714,285 A$0.02 A$64,999
31. Jul 18 Buy Ian Dixon Individual 31. Jul 18 31. Jul 18 1,428,571 A$0.02 A$25,000
31. Jul 18 Buy Patricia Boero Individual 31. Jul 18 31. Jul 18 1,428,571 A$0.02 A$25,000
31. Jul 18 Buy Donald Channer Individual 31. Jul 18 31. Jul 18 3,428,571 A$0.02 A$59,999
X
Management checks
We assess Medigard's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medigard has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MGZ News

Simply Wall St News

The Medigard Share Price Has Gained 33% And Shareholders Are Hoping For More

On the other hand the share price is higher than it was three years ago. … Arguably you'd have been better off buying an index fund, because the gain of 33% in three years isn't amazing. … Investors will be hoping that Medigard can make progress and gain better traction for the business, before it runs low on cash.

Simply Wall St -

Have Insiders Been Buying Medigard Limited (ASX:MGZ) Shares?

Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. … So we'll take a look at whether insiders have been buying or selling shares in Medigard Limited (ASX:MGZ). … But logic dictates you should pay some attention to whether insiders are buying or selling shares.

Simply Wall St -

Is Medigard Limited (ASX:MGZ) A Volatile Stock?

Volatility is considered to be a measure of risk in modern finance theory. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

How Much Of Medigard Limited (ASX:MGZ) Do Insiders Own?

Conversely, insiders often decrease their ownership over time. … Taking a look at the our data on the ownership groups (below), it's seems that. … We can zoom in on the different ownership groups, to learn more about MGZ

Simply Wall St -

Should You Sell Medigard Limited (ASX:MGZ) For This Reason?

A crucial question to bear in mind when you’re an investor of an unprofitable business, is whether the company will have to raise more capital in the near future. … Given that Medigard is spending more money than it earns, it will need to fund its expenses via external sources of capital. … Looking at Medigard’s latest financial data, I will gauge when the company may run out of cash and need to raise more money.

Simply Wall St -

Who Really Owns Medigard Limited (ASX:MGZ)?

Today, I will be analyzing Medigard Limited’s (ASX:MGZ) recent ownership structure, an important but not-so-popular subject among individual investors. … Insider Ownership Another important group of shareholders are company insiders. … Thus, investors should dig deeper into MGZ's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: Institutional ownership in MGZ is not at a level that would concern investors.

Simply Wall St -

When Will Medigard Limited (ASX:MGZ) Run Out Of Money?

See our latest analysis for Medigard What is cash burn? … Cash burn is when a loss-making company spends its equity to fund its expenses before making money from its day-to-day business. … The measure of how fast Medigard goes through its cash reserves over time is called the cash burn rate.

Simply Wall St -

Before You Buy Medigard Limited's (ASX:MGZ), Consider This

Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … With a market cap of AU$2.26M, MGZ falls within the small-cap spectrum of stocks, which are found to experience higher relative risk compared to larger companies. … However, this is the opposite to what MGZ’s actual beta value suggests, which is higher stock volatility relative to the market.

Simply Wall St -

Why Medigard Limited's (ASX:MGZ) Ownership Structure Is Important

In this article, I'm going to take a look at Medigard Limited’s (ASX:MGZ) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Insider Ownership Insiders form another group of important ownership types as they manage the company's operations and decide the best use of capital. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: With a low level of institutional ownership, investors in MGZ need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

What's The Outlook For Loss-Making Medigard Limited (ASX:MGZ)?

Additional cash raising may dilute the value of your shares, and since MGZ is currently burning more cash than it is making, it’s likely the business will need funding for future growth. … Companies with high cash burn rates can eventually turn into ashes, which makes it the biggest risk an investor in loss-making companies face. … ASX:MGZ Income Statement Oct 20th 17 When will MGZ need to raise more cash?

Simply Wall St -

MGZ Company Info

Description

Medigard Limited develops various medical instruments in Australia. The company designs, develops, and manufactures blood collection devices and flash back needles. Medigard Limited was founded in 1999 and is based in Main Beach, Australia.

Details
Name: Medigard Limited
MGZ
Exchange: ASX
Founded: 1999
A$2,706,006
135,300,327
Website: http://www.medigard.com.au
Address: Medigard Limited
30 Tedder Avenue,
Suite 14,
Main Beach,
Queensland, 4217,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX MGZ Ordinary Shares Australian Securities Exchange AU AUD 05. Feb 2004
Number of employees
Current staff
Staff numbers
0
Medigard employees.
Industry
Health Care Supplies
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 10:31
End of day share price update: 2019/03/04 00:00
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.